RI 002

Drug Profile

RI 002

Alternative Names: IGIV - ADMA Biologics; Immune globulin intravenous - ADMA Biologics; Respiratory syncytial virus immune globulin - ADMA Biologics; RI-001; RI-002

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ADMA Biologics; Baylor College of Medicine
  • Developer ADMA Biologics
  • Class Antivirals; Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Immunodeficiency disorders

Most Recent Events

  • 15 Nov 2017 ADMA Biologics receives patent allowance for methods and compositions for the treatment of immunodeficiency in USA
  • 31 Jul 2017 ADMA Biologics has patent protection for RI 002 in USA
  • 07 Jun 2017 ADMA biologics announces intention to refile BLA to US FDA for Primary immune deficiency disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top